Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine versus placebo + azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
NL-OMON60363Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Venetoclax + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Overall survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON60363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60363.